Incretin Atlas › Trials › US phase 2 (NCT06124807)
US phase 2 (NCT06124807)
Mazdutide · obesity
Design
- Molecule(s)
- Mazdutide
- Population
- obesity
- Phase
- 2
- Participants
- 179
- Duration
- 32 weeks
- Registry
- NCT06124807
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3-6 mg (3 mg to week 32) | obesity | 32 | 179 | −7.3 % vs −0.9 % Δ −6.4 pp | — | — | — | — | — | — | — | — | press release |
| 10 mg | obesity | 32 | 179 | −15.6 % vs −0.9 % Δ −14.7 pp | — | — | — | — | — | — | — | — | press release |
| 16 mg | obesity | 32 | 179 | −18.1 % vs −0.9 % Δ −17.2 pp | — | — | 20.0 | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (4)
- 3-6 mg (3 mg to week 32) · weight_eff · publication
At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
- 10 mg · weight_eff · publication
At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
- 16 mg · weight_eff · publication
At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
- 16 mg · ae_dc · publication
discontinuation of study treatment due to adverse events occurred most frequently with 16 mg (20%)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: US phase 2 (NCT06124807). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/us-phase-2-nct06124807/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.